Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1174167 | 0.80 | LMNA (0.50) | NPC1EPHX2LMNAKMT2AMEN1 | |
| SCHEMBL12869309 | 0.78 | RAB9A (0.34) | NPC1EPHX2GSTP1GSTM2LMNA | |
| SCHEMBL1175345 | 0.78 | PKM (0.47) | NPC1LMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL2523852 | 0.75 | EPHX2 (0.44) | NPC1EPHX2GSTP1GSTM2LMNA | |
| SCHEMBL7797109 | 0.72 | ALDH1A1 (0.42) | NPC1LMNAKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1175508 | 0.70 | EPHX2 (0.33) | NPC1EPHX2GSTP1GSTM2KMT2A | |
| SCHEMBL6535061 | 0.67 | KMT2A (0.60) | EPHX2KMT2AMEN1HTTALDH1A1 | |
| SCHEMBL1175212 | 0.67 | LMNA (0.50) | NPC1EPHX2LMNAKMT2AMEN1 | |
| SCHEMBL17899650 | 0.62 | KMT2A (0.46) | EPHX2LMNAKMT2AMEN1ALDH1A1 | |
| SCHEMBL12610613 | 0.62 | ALDH1A1 (0.49) | NPC1EPHX2LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8624040-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2010151317-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | NPC1 1431/4885EPHX2 1446/4885GSTP1 864/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | NPC1 1431/4885EPHX2 1446/4885GSTP1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.